



03 C0

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(s): Demuth, et al.

EXAMINER: Not Yet Assigned

SERIAL NO.: 09/745,776

GROUP: Not Yet Assigned

FILED: December 22, 2000

DOCKET: 20784/4

FOR: PRODRUGS OF DP IV INHIBITORS

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to the:  
Assistant Commissioner of Patents, Washington, D.C. 20231 on March 30, 2001.

Renee Mason-Salewala

Renee M. Mason-Salewala

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to Applicant(s) duty of disclosure, the information listed in the attached form PTO-1449 is brought to the attention of the Examiner. Copies of the listed items are enclosed.

The citation of the listed items is not a representation that they constitute a complete or exhaustive listing of the relevant art or that the references are prior art. The items listed are submitted in good faith, but are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner of these particular items, they will assist in identifying fields of search and in making as full and complete a search as possible.

The filing of this information disclosure statement is not an admission that the

information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with the requirement under 37 C.F.R. 1.98 (3)(i), the following are concise explanations of the relevance, as presently understood, with regard to those items submitted herewith that are not in the English language:

**GERMAN LANGUAGE DE 196 16 486** apparently relates to the use of a method in which reducing in the blood of a mammal, by administration of effectors, the enzyme activity of dipeptidyl peptidase (DP IV) or enzyme activity similar to DP IV causes the blood sugar level to drop below the glucose concentration, characteristic of hyperglycemia, in the serum of the treated organism, preventing or alleviating metabolic anomalies such as glucosuria, hyperlipidemia, possible serious metabolic acidosis, diabetes mellitus which result from higher concentrations of glucose in the blood.


- This information disclosure statement is being filed within three (3) months of the filing date of this application.
- This information disclosure statement is being filed within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application.**
- To the best of Applicant(s) knowledge, this information disclosure statement is being filed before the date of mailing of a first Office Action on the merits in connection with this case.**
- Enclosed herewith is a certificate under 37 C.F.R. § 1.97(e)(1).
- Enclosed herewith is a petition under 37 C.F.R. § 1.97(d)(ii).
- Enclosed by check is the petition fee of \$130.00.  
(37 C.F.R. § 1.17(I)(1))

Demuth et al.  
USSN: 09/745,776  
Page 3 of 4

- Please charge the \$130.00 petition fee to Deposit Account No. 50-0369.
- Enclosed by check is the \$240.00 fee required by 37 C.F.R. §1.17(p).
- Please charge the \$240.00 fee required by 37 C.F.R. § 1.17(p) to Deposit Account No. 04-1121.
- Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or §1.17 at any time during pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 50-0369. Also, in the event any extensions of time for responding and/or a petition under 37 C.F.R. §1.17 are required for the pending application(s), please treat this paper as a petition to extend the time and/or enter this Information Disclosure Statement as required and charge Deposit Account No 50-0369 therefor. **TWO (2) COPIES OF THIS SHEET ARE ENCLOSED.**

The claims of the application as now presented are believed to patentably distinguish over the prior art and to be in condition for allowance. Early and favorable consideration of this application are respectfully requested.

Respectfully submitted,

  
Mark A. Hofer  
Reg. No. 30,068  
Attorney for Applicants  
Brown, Rudnick, Freed & Gesmer, P.C.  
One Financial Center  
Boston, MA 02111  
Tel: 617-856-8327  
Fax: 617-856-8201